ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells.
Sign Up to like & getrecommendations! Published in 2017 at "Anticancer research"
DOI: 10.21873/anticanres.12115
Abstract: BACKGROUND/AIM ESE-1/Elf3 controls transformation properties in mammary epithelial cells, and is most clinically relevant in HER2+ breast cancer. Herein we showed that ESE-1 knockdown inhibits tumorigenic growth in HER2+, trastuzumab-resistant HR20 (derived from HER2+ ER+… read more here.
Keywords: her2 breast; ese knockdown; trastuzumab resistant; breast cancer ... See more keywords